Navigation Links
Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
Date:6/1/2009

ORLANDO - When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.

The findings, presented today at the American Society of Clinical Oncology's annual meeting, mark the first clinical benefit of a small molecule targeted agent and standard chemotherapy in combination for lung cancer. Roy Herbst, M.D., Ph.D., professor and chief of the section of M. D. Anderson's Department of Thoracic/Head and Neck Medical Oncology, presented the findings on ASCO's press program.

"This study shows that an oral tyrosine kinase inhibitor can be combined with chemotherapy safely and effectively to provide systematic benefit to patients with this life-threatening disease," said Herbst. "This study will have immediate clinical implications. Still, we need to build on this research and turn our focus toward better identifying molecular markers involved, with the ultimate goal of personalizing our patient's care."

The therapy is unique in that it's a dual inhibitor and targets the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). It is the first single agent in lung cancer to target both receptors, said Herbst, the study's international principal investigator.

"Both receptors are active in lung cancer. EGFR targets the tumor cell and VEGF targets the blood vessels, so, with vandetanib, we're really targeting the entire tumor environment at the same time," explained Herbst. "As a dual inhibitor, it also may provide cost-savings to patients in that they can now potentially take one therapy instead of two."

According to the American Cancer Society, lung cancer accounts for the most cancer-related deaths. In 2009, 219,440 are expected to be diagnosed and 159,390 will likely die from the disease.

The ZODIAC, (Zactima in cOmbination with Docetaxel In non-smAll cell lung Cancer) study enrolled 1,391 patients with non-small cell lung cancer from 198 centers between May 2006 and April 2008; all had received chemotherapy previously. Participants were randomized to receive either docetaxel and placebo, or docetaxel and vandetanib. The median follow-up was 12.8 months and the study's primary endpoint was progression-free survival.

Patients in the combination arm had a 21 percent reduction in disease progression, compared to those who received docetaxel alone (hazard ratio, .79), and their median progression-free survival was 17.3 weeks. In contrast, the median progression-free survival in the control arm was 14 weeks. While it trended positive, however, there was no statistical difference in overall survival in the two groups. There was a statistically significant improvement in the time to worsening of symptoms (hazard ratio, .77).

"Obviously, our ultimate goal is to always improve survival for our patients, however the improved time to progression with less of a number of significant effects is important," said Herbst. "This is certainly a drug, where, if we could identify molecular parameters that predict response, we could some day take a group that's receiving docetaxel and vandetanib and see them do even better. We're not there yet, but hopefully this study will serve as the foundation for the merger of personalization and discovery with the now-proven safety and efficacy."

In terms of side effects, patients who received vandetanib experienced more diarrhea, rash and neutropenia. However, they experienced less of the significant side effects - nausea, vomiting, and anemia - than those who received docetaxel alone. The lack of significant side effects is quite striking, said Herbst, because other agents that target VEGF are associated with increased toxicity, including pulmonary bleeding.

As follow up, Herbst plans to update the survival data later this year. Other studies with vandetanib in lung cancer as a single agent, as well as in thyroid cancer, are currently ongoing.


'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
832-264-8893
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib
2. Vaccine shows therapeutic promise against advanced melanoma
3. Study shows gay couples want legal rights, regardless of marriage
4. Immune-Based Lymphoma Treatment Shows Promise
5. Avastin Shows No Benefit Against Early Stage Colon Cancer
6. Study shows drug combination improves outcome for advanced non-small cell lung cancer
7. Tool Shows Promise for Measuring Productivity of Mid-Level Oncology Providers
8. New Study Shows Probiotics Linked to Metabolism
9. Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
10. Cottonseed-based drug shows promise in treating severe brain cancer
11. Dementia drugs may put some patients at risk, Queens study shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
(Date:1/16/2017)... ... 2017 , ... Permobil has just completed the acquisition of ... systems has a well-earned reputation for premium quality, with a focus on fit ... in the custom seating business, which enjoys strong demand, and it complements Permobil’s ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water educator, researcher and ... nationally syndicated radio program, The Sharon Kleyne Hour Power of Water, Global Climate ...
(Date:1/16/2017)... ... January 16, 2017 , ... San Francisco dentist, Dr. Ben ... in 3-D scanning device which is capable of taking digital impressions of teeth and ... such as CAD CAM restorations , in terms of speed, efficiency and patient ...
(Date:1/15/2017)... ... 15, 2017 , ... Going above and beyond the practical ... better communities around the world by offering the Gensuite team and their services ... team members to become involved in a cause that is bigger than themselves ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... physicians in eight Bay Area counties for 2017. Almost 1,000 nominations were submitted ... managing the award process. Results were announced the magazine’s January 2017 issue ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... Jan. 16, 2017  An aneurysm develops due to the ... Aneurysms can occur in any artery, it happens ... that supplies blood to legs. Most aortic aneurysms occur in ... and are referred as abdominal aortic aneurysms, sometimes in the ... the aorta in the abdomen is about 2 cm but ...
(Date:1/16/2017)... ® Inc., a leading manufacturer and marketer of imaging and ... Spectrum TM Single-Use video laryngoscopes. The new Spectrum ... Reduction TM technology, which actively optimizes image quality. ... ... Introducing another bright idea from GlideScope(R) Video Laryngoscopes: ...
(Date:1/16/2017)... 16, 2017  According to Kalorama Information, the ... valued at $4.9 billion for 2016.  The growing ... an aging population with significant diagnostic needs, along ... propelling the market for the modality.  The healthcare ... , focuses on the worldwide market, providing market ...
Breaking Medicine Technology: